Table 1.

Clinicopathological data of sporadic and Lynch-associated ovarian carcinoma

	Sporadic				Lynch-associatedc
	Clear cell	Endometrioida	Serous	Total	Clear cell	Endometrioid	Total
No. of cases	36	28	20	84	7	12	19
Grade
G1	NA	11	0	11	NA	6	6
G2 and G3	NA	17	20	37	NA	5	5
Stage
I and II	22	14	3	39	6	9	15
III and IV	14	14	17	45	1	3	4
Overall MMR status
MMR deficient	6 (17%)	4 (14%)	1 (5%)	11 (13%)	7 (100%)	11 (92%)	18 (95%)
MMR proficient	30 (83%)	24 (86%)	19 (95%)	73 (87%)	0 (0%)	1 (8%)	1 (5%)
Average no. of TSGs methylated out of 24b	2.5	3.0	0.6		5.0	3.8
Average no. of TSGs methylated out of 13c	6.7	6.4	2.8		8.3	6.4

^aOne of the Lynch endometrioid tumors is borderline tumor, which is not graded.

^bNiskakoski et al.¹⁸

^cThe predisposing mutation affected MLH1 in 15 and MSH2 in 4 cases (see Niskakoski et al.¹⁸ for details).